Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11


Structural States of Hdm2 and HdmX: X-ray Elucidation of Adaptations and Binding Interactions for Different Chemical Compound Classes.

Kallen J, Izaac A, Chau S, Wirth E, Schoepfer J, Mah R, Schlapbach A, Stutz S, Vaupel A, Guagnano V, Masuya K, Stachyra TM, Salem B, Chene P, Gessier F, Holzer P, Furet P.

ChemMedChem. 2019 Jul 17;14(14):1305-1314. doi: 10.1002/cmdc.201900201. Epub 2019 May 27.


In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitor.

Vaupel A, Holzer P, Ferretti S, Guagnano V, Kallen J, Mah R, Masuya K, Ruetz S, Rynn C, Schlapbach A, Stachyra T, Stutz S, Todorov M, Jeay S, Furet P.

Bioorg Med Chem Lett. 2018 Nov 1;28(20):3404-3408. doi: 10.1016/j.bmcl.2018.08.027. Epub 2018 Aug 26.


Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201.

Jeay S, Ferretti S, Holzer P, Fuchs J, Chapeau EA, Wartmann M, Sterker D, Romanet V, Murakami M, Kerr G, Durand EY, Gaulis S, Cortes-Cros M, Ruetz S, Stachyra TM, Kallen J, Furet P, Würthner J, Guerreiro N, Halilovic E, Jullion A, Kauffmann A, Kuriakose E, Wiesmann M, Jensen MR, Hofmann F, Sellers WR.

Cancer Res. 2018 Nov 1;78(21):6257-6267. doi: 10.1158/0008-5472.CAN-18-0338. Epub 2018 Aug 22.


A critical assessment of the synthesis and biological activity of p53/human double minute 2-stapled peptide inhibitors.

Wallbrecher R, Chène P, Ruetz S, Stachyra T, Vorherr T, Brock R.

Br J Pharmacol. 2017 Aug;174(16):2613-2622. doi: 10.1111/bph.13834. Epub 2017 Jul 6.


Bioorthogonal Probes for the Study of MDM2-p53 Inhibitors in Cells and Development of High-Content Screening Assays for Drug Discovery.

D'Alessandro PL, Buschmann N, Kaufmann M, Furet P, Baysang F, Brunner R, Marzinzik A, Vorherr T, Stachyra TM, Ottl J, Lizos DE, Cobos-Correa A.

Angew Chem Int Ed Engl. 2016 Dec 23;55(52):16026-16030. doi: 10.1002/anie.201608568. Epub 2016 Nov 22.


Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.

Stachyra T, Péchereau MC, Bruneau JM, Claudon M, Frère JM, Miossec C, Coleman K, Black MT.

Antimicrob Agents Chemother. 2010 Dec;54(12):5132-8. doi: 10.1128/AAC.00568-10. Epub 2010 Oct 4.


In vitro activity of the {beta}-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases.

Stachyra T, Levasseur P, Péchereau MC, Girard AM, Claudon M, Miossec C, Black MT.

J Antimicrob Chemother. 2009 Aug;64(2):326-9. doi: 10.1093/jac/dkp197. Epub 2009 Jun 2.


Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases.

Black MT, Stachyra T, Platel D, Girard AM, Claudon M, Bruneau JM, Miossec C.

Antimicrob Agents Chemother. 2008 Sep;52(9):3339-49. doi: 10.1128/AAC.00496-08. Epub 2008 Jul 14.


In vitro activity of AVE1330A, an innovative broad-spectrum non-beta-lactam beta-lactamase inhibitor.

Bonnefoy A, Dupuis-Hamelin C, Steier V, Delachaume C, Seys C, Stachyra T, Fairley M, Guitton M, Lampilas M.

J Antimicrob Chemother. 2004 Aug;54(2):410-7. Epub 2004 Jul 14.


Fluorescence detection-based functional assay for high-throughput screening for MraY.

Stachyra T, Dini C, Ferrari P, Bouhss A, van Heijenoort J, Mengin-Lecreulx D, Blanot D, Biton J, Le Beller D.

Antimicrob Agents Chemother. 2004 Mar;48(3):897-902.


Hemoglobin, horseradish peroxidase, and heme-bovine serum albumin as biocatalyst for the oxidation of dibenzothiophene.

Stachyra T, Guillochon D, Pulvin S, Thomas D.

Appl Biochem Biotechnol. 1996 Jun;59(3):231-44.


Supplemental Content

Loading ...
Support Center